INmune Bio

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell INmune Bio and other ETFs, options, and stocks.

About INMB

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate.

CEO

Raymond J. Tesi

CEORaymond J. Tesi

Employees

Employees22

Headquarters

Boca Raton, Florida

HeadquartersBoca Raton, Florida

Founded

2015

Founded2015

Employees

Employees22

INMB Key Statistics

Market cap

187.77M

Market cap187.77M

Price-Earnings ratio

-4.15

Price-Earnings ratio-4.15

Dividend yield

—

Dividend yield—

Average volume

573.51K

Average volume573.51K

High today

—

High today—

Low today

—

Low today—

Open price

$7.99

Open price$7.99

Volume

0.00

Volume0.00

52 Week high

$10.50

52 Week high$10.50

52 Week low

$4.32

52 Week low$4.32

Analyst ratings

100%

of 6 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own INMB. This list is generated using Robinhood data, and it’s not a recommendation.

INmune Bio

Why Robinhood?

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. Show more

INMB Key Statistics

Analyst ratings

100%

People also own

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate.